Daniel Barber - 15 Jun 2026 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Reporting relationship: President and CEO
Issuer ticker: AQST
Reported as of: 15 Jun 2026
Net transaction value: -$104,010
SEC form: 4
Accepted by SEC: 16 Jun 2026, 16:09:00 UTC
Prior SEC filing: 18 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Thomas Zalewski, as Attorney-In-Fact

Key filing fact

Daniel Barber filed Form 4 for Aquestive Therapeutics, Inc. (AQST) on 16 Jun 2026.

Key facts

This page summarizes Daniel Barber's Form 4 filing for Aquestive Therapeutics, Inc. (AQST).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 16 Jun 2026, 16:09.

Change

Previous filing in this sequence was filed on 18 May 2026.
Current net transaction value: -$104,010.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001742266 Primary reporting owner

Barber Daniel

Relationship: President and CEO
Address: C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN
Signature: /s/ Thomas Zalewski, as Attorney-In-Fact
Signature date: 17 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AQST transaction

Common Stock

Sale

Transaction value: $104,010
Shares: -25,000
Change %: -3.8%
Price: $4.16
Shares after: 635,574
Date: 15 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

The reported transaction involves sale transactions from $4.14 to $4.235 per share. The weighted average price per share was $4.1604. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price.